Kazuyuki Mizuno

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.

Journal: Journal of gastroenterology

Published: April 08, 2026

Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis.

Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

Published: March 03, 2026

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Journal: Cancer science

Published: December 06, 2025

Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review.

Journal: Japanese journal of clinical oncology

Published: July 24, 2025

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

Journal: Cancer medicine

Published: May 18, 2025

Author's reply: Pancreatic injury in immune checkpoint inhibitor therapy: Clinical management challenges and considerations.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 17, 2025

Author's reply: Letter to the editor: Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 17, 2025

Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis.

Journal: Liver cancer

Published: February 11, 2025

Steroid initiation dose and duration of steroid reduction for immune checkpoint inhibitor-induced liver injury.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: February 10, 2025

Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: December 08, 2024

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.

Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis.

Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis.

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review.

Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review.

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

Author's reply: Pancreatic injury in immune checkpoint inhibitor therapy: Clinical management challenges and considerations.

Author's reply: Pancreatic injury in immune checkpoint inhibitor therapy: Clinical management challenges and considerations.

Author's reply: Letter to the editor: Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

Author's reply: Letter to the editor: Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis.

Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis.

Steroid initiation dose and duration of steroid reduction for immune checkpoint inhibitor-induced liver injury.

Steroid initiation dose and duration of steroid reduction for immune checkpoint inhibitor-induced liver injury.

Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events.

Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events.

Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.

Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.